MEK1/2 inhibition promotes taxotere® lethality in mammary tumors in vivo

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1332-1339

  Yacoub, Adly ^a,c   Gilfor, Donna ^a   Hawkins, William ^a   Park, Margaret A ^a   Hanna, David ^a   Hagan, Michael P ^c   Curiel, David T ^e   Fisher, Paul B ^d   Grant, Steven ^a,b   Dent, Paul ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NONE   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

Breast; CI 1040; Docetaxel; In vivo; Inhibitor; Kinase; PD184352; Taxotere; Tumor

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PACLITAXEL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; ENZYME INHIBITION; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RADIATION DOSE FRACTIONATION; TUMOR VOLUME;

EID: 33751115715     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3215     Document Type: Article

References (41)

1. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001; 4:3-7.
2. Rowinsky EK, Onetto N, Canetta RM and Arbuck SG Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19:646-62.
3. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27:221-33.
4. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5:495-505.
5. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993; 7:563-68.
6. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents. 2002; 2:1-17.
7. Pryor DE, O'Brate A, Bilcer G, Diaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002; 41:9109-15.
8. Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 2001; 60:143-54.
9. Wang S, Guo C-Y, Castillo A, Dent P and Grant S Effect of bryostatin 1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells. Biochem Pharmacol 1998; 56:635-44.
10. Shen SC, Huang TS, Jee SH, Kuo ML. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ. 1998; 9:23-9.
11. Yamamoto K, Ichijo H and Korsmeyer SJ BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 1999; 19:8469-78.
12. Minden A and Karin M Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997; 1333:F85-F104.
13. Fan M and Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 4:253-67.
14. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998; 12:1843-50.
15. Cobb MH MAP kinase pathways. Prog Biophys Mol Biol 1999; 71:479-500.
16. Dent, P, Yacoub, A, Fisher, PB, Hagan, MP and Grant, S MAPK pathways in radiation responses. Oncogene 2003; 22:5885-5896.
17. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M and Lord JM Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000; 256:34-41.
18. Xia Z, Dickens M, Raingeaud J, Davis R and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash DC) 1995; 270:1326-31.
19. Kang, C-D, Yoo S-D, Hwang B-W, Kim K-W, Kin D-W, Kim C-M, Kim S-H and Chung B-S The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res 2000; 24:527-34.
20. Suzaki Y, Yoshizumi M, Kagami S, Koyama AH, Taketani Y, Houchi H, Tsuchiya K, Takeda E, Tamaki T. Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J Biol Chem 2002; 277:9614-21.
21. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. (2002) Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002; 132:293-301.
22. Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270:27489-94.
23. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999; 10:2493-506.
24. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-16.
25. Wang X, Zhai Y and Ferrell J A role for mitogen-activated protein kinase in the spindle assembly checkpoint in XTC cells. J Cell Biol 1997; 137:433-43.
26. Cross DE and Smythe C PD98059 prevents establishment of the spindle assembly check-point and inhibits G2-M transition in meiotic but not mitotic cell cycles in Xenopus. Exp Cell Res 1998; 241:12-22.
27. Wright JH, Munar E, Jameson DR, Andreassen PR, Margolis RL, Seger R, Krebs EG. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci U S A 1999; 96:11335-40.
28. Huang Y, Sheikh MS, Fornace AJ, Jr and Holbrook NJ Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 1999; 18:3431-39.
29. Stone AA and Chambers TC Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254:110-19.
30. Shtil AA, Mandlekar S, Yu R, Walter RJ, Hagen K, Tan TH, Roninson IB and Kong AN Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 1999; 18:377-84.
31. Lieu C-H, Liu C-C, Yu T-H, Chen K-D, Chang Y-N and Lai YK Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Diff 1998; 9:767-76.
32. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Perez-Soler R, Horwitz SB. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005; 65:2854-2860.
33. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83:288-291.
34. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther. 2003; 2:670-676.
35. McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P. Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells. Cancer Biol Ther 2002; 1:243-253.
36. MacKeigan, JP, Taxman, DJ, Hunter, D, Earp, HS, Graves, LM and Ting, JPY. Inactivation of the Antiapoptotic Phosphatidylinositol 3-Kinase-Akt Pathway by the Combined Treatment of Taxol and Mitogen-activated Protein Kinase Kinase Inhibition. Clin. Cancer Res. 2002; 8:2091-99.
37. Hayne C, Tzivion G, Luo Z. Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J Biol Chem. 2000; 275:31876-82.
38. Lee LF, Li G, Templeton DJ and Ting JP Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase. J Biol Chem 1998; 273:28253-28260
39. Fan M, Du L, Stone AA, Gilbert KM and Chambers TC Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistant normal fluctuations at G2-M. Cancer Res 2000; 39:6403-7.
40. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA and Chambers TC Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 2000; 275:29980-85
41. Blagosklonny MV, Chuman Y, Bergan RC and Fojo T Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 1999; 13:1028-36